5 times higher), we reasoned that selenium-dependent Gpx activity in BALF should reflect GPX3 activity
Cell types were annotated based on known immune cell marker genes, including: CD4+ T cells (CD2, CD4, CCR7, CD3D), CD8+ T cells (CD8A, GNLY, GZMB), NK cells (LTB, NKG7), plasma cells (XBP1, CD27), B cells (MS4A1, CD79A), and monocytes (CD14, LYZ, FCGR3A)
Quick Comparison Feature CagriSema Retatrutide Development owner Novo Nordisk Eli Lilly Core strategy Combination therapy Single-molecule multi-agonist Pathways Amylin + GLP-1 GIP + GLP-1 + glucagon Main components Cagrilintide + semaglutide Retatrutide (LY3437943) 2026 status Phase 3 / regulatory-watch candidate Phase 3 TRIUMPH program Best-fit research question Can amylin extend GLP-1 results
Research applications: cytoprotection, angiogenesis...